Fig 1.
Patient recruitment and follow-up process.
* G1: Metformin alone, G2: Metformin + glimepiride, G3: Metformin + glyburide, G4: Metformin + Sitagliptin, G5: Metformin + Saxagliptim.
Table 1.
Baseline characteristics of sociodemographic and primary outcomes.
Fig 2.
a. Mean distribution of BMI over 24 months of the study. b. Mean distribution of body weight over 24 months of the study.
Table 2.
Differential data analysis for the groups in the study (post 24 months).
Table 3.
ASCVD risk assessment and comparison between different cohorts.